ClinicalTrials.gg
Active, not recruitingNCT05469009Updated Jan 22, 2026

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

An Early Phase 1 interventional study of Aducanumab and Exablate Model 4000 Type 2 in Mild Cognitive Impairment and Alzheimer Disease 1, sponsored by Ali Rezai. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Ali Rezai · Early Phase 1, Interventional, and Device feasibility

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,423 studies in Cognitive Dysfunction with a site in United States — 330 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Planned enrollment
979th of 1,147
15 · median 59
Started
2022
with 106 others
Phase 1
102 of 1,423
20 open now
Primary completion
2029-07
later than 384 of 431 live
Registered
991st of 1,423
by date

Among the 1,423 studies in Cognitive Dysfunction with a site in United States, this one is the 979th largest by planned enrollment of the 1,147 interventional ones that give a count, is one of 107 that started in 2022, is one of 102 in phase 1, reaches primary completion later than 384 of the 431 other live ones, and was the 991st registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

330 of the 1,423 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

325 more — sign in →

All 330 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,423 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and feasibility of administering standard of care monoclonal antibody (mAb) infusion therapy in combination with opening the blood-brain barrier with the Exablate Model 4000 Type 2 device in patients with mild Alzheimer's disease (AD) or mild cognitive impairment (MCI).

Read the detailed description

The primary objectives of this study is to evaluate the safety and feasibility of BBBO (blood-brain barrier opening) using the Exablate Model 4000 Type 2 in the setting of standard aducanumab or lecanemab therapy among patients with mild cognitive impairment (MCI) or mild Alzheimer's disease (AD) with confirmed β-amyloid, who are eligible for aducanumab or lecanemab infusion therapy, and to also evaluate the safety of the BBO procedure through patient examination (neurological and cognitive/behavioral) and MRI assessments during the treatment and follow-up.

The secondary objectives of this study is to determine the effect of BBBO in patients with MCI or mild AD treated with aducanumab or lecanemab on brain β-amyloid plaque measured by amyloid positron emission tomography (PET), as well as to assess the clinical impact of BBBO with standard aducanumab or lecanemab therapy, if any, as assessed with ADAS Cog 11 and MMSE over time following BBBO.

03

Conditions studied

  • Mild Cognitive Impairment
  • Alzheimer Disease 1
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to give
  • Probable mild cognitive impairment due to AD
  • Modified Hachinski Ischemia Scale (MHIS) score of \<= 4
  • (MMSE) scores > 21+.
  • Short form Geriatric Depression Scale (GDS) score of \<= 7
  • Amyloid PET scan consistent with the presence of β-amyloid (A+)
  • Able to communicate sensations during the Exablate MRgFUS procedure
  • Able to attend all study visits (i.e., of 1 year or more)

Exclusion criteria

Exclusion Criteria:

  • MRI findings:
  • Significant cardiac disease or unstable hemodynamic status
  • History of a liver disease, bleeding disorder, coagulopathy or a history of spontaneous hemorrhage
  • Known cerebral or systemic vasculopathy
  • Significant depression (GDS > 7) and/or at potential risk of suicide (C-SSRS > 2)
  • A severity score of 2 or more on any of the 'Delusions', 'Hallucinations' or 'Agitation/Aggression' subscales of the Neuropsychiatry Inventory (NPI-Q)
  • Known sensitivity/allergy to gadolinium(gadobutrol), DEFINITY or its components, or 18F-florbetaben.
  • Known to DEFINITY or its components.
  • Any to MRI scanning
  • Untreated, uncontrolled sleep apnea
  • History of untreated or uncontrolled seizure disorder or epilepsy.
  • Impaired renal function
  • Does not have a reliable caregiver
  • Currently in a clinical trial involving an product or non-approved use of a drug or device or in any other type of medical research.
  • Respiratory: chronic pulmonary disorders
  • History of recent drug or alcohol use disorder who may be at higher risk for seizure or infection.
  • Positive (HIV) which can lead to increased entry of HIV into the brain parenchyma leading to HIV encephalitis.
  • Potential blood-borne infections, which can lead to increased entry to brain parenchyma leading to meningitis or brain abscess.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Early Phase 1
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Infusion plus Exablate BBBO Treatment

    Intravenous infusion of Aducanumab or Lecanemab every 2-4 weeks (per standard of care) followed by blood brain barrier opening by FUS.

    Drug: Aducanumab · Device: Exablate Model 4000 Type 2 · Drug: Lecanemab

Interventions

  • Standard aducanumab therapy will be given by intravenous infusion every 4 weeks for 6 cycles with blood brain barrier opening

    Also known as: Aduhelm

  • DeviceExablate Model 4000 Type 2

    The Exablate Model 4000 will be utilized for the BBBO (blood-brain barrier opening) after each cycle of Aducanumab or Lecanemab administered per label.

    Also known as: Focused Ultrasound

  • Standard lecanemab therapy will be given by intravenous infusion every 2 weeks for up to 6 cycles with blood brain barrier opening

    Also known as: Leqembi

06

What researchers measure

Primary outcomes

  1. Treatment intervention related adverse events

    The total number of adverse events following each treatment through end of the study

    Time frame: From baseline, up to 5 year post last treatment

  2. Treatment intervention related serious adverse events

    The total number of serious adverse events following each treatment through end of the study

    Time frame: From baseline, up to 5 year post last treatment

Secondary outcomes

  1. Beta-Amyloid plaques within the brain

    Beta-Amyloid uptake value measured by Amyloid PET scan

    Time frame: From baseline, up to 5 year post last treatment

  2. Cognitive performance (ADAS COG 11)

    Change in cognitive performance using the Alzheimer's Disease Assessment Cognitive Subscale, rating scores from 0-70. The greater the dysfunction, the greater the score. A score of 70 represents the most severe impairment and 0 represents the least impairment.

    Time frame: From baseline, up to 5 year post last treatment

  3. Cognitive performance (MMSE)

    Change in cognitive performance using the Mini Mental Status Exam, rating scores from 0-30. 25 or higher being classed as normal. A score below 24 is considered abnormal, indicating possible cognitive impairment.

    Time frame: From baseline, up to 5 year post last treatment

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jul 2029, 84 months after the start.

Of 54 non-industry phase 1 interventional studies under Cognitive Dysfunction, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 84 months is above that.

Counting every sponsor, half of 80 studies reached it within 29 months; a quarter within 13 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2022
First posted
Jul 21, 2022
StartActual
Jul 14, 2022
Primary completionEst.
Jul 2029
CompletionEst.
Jul 2029
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05469009
Lead sponsor
Ali Rezai
Collaborators
InSightec
Responsible party
Ali Rezai (Neurosurgeon, West Virginia University) — Sponsor-investigator
First posted
Jul 21, 2022
Start date
Jul 14, 2022
Primary completion
Jul 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Jan 22, 2026

Study contacts

Ali Rezai, MD, FAANS
principal investigator · WVU Rockerfeller Neuroscience Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aducanumab · Lecanemab

Start the discussion